# Macrophages in Autoimmune Liver Diseases: From Immune Homeostasis to Precision-Targeted Therapy

## TL;DR

This paper explores how macrophages contribute to autoimmune liver diseases and how their programmed cell death processes could lead to new targeted therapies.

## Contribution

The paper introduces new insights into macrophage-driven immunoregulation and programmed cell death in autoimmune liver diseases.

## Key findings

- Macrophages show polarization imbalance and increased monocyte recruitment in autoimmune liver diseases.
- Programmed cell death processes like necroptosis and pyroptosis influence macrophage function and disease progression.
- Understanding macrophage-immune interactions may lead to novel personalized therapies for autoimmune liver diseases.

## Abstract

Autoimmune liver diseases (AILDs) represent a diverse spectrum of chronic inflammatory conditions characterized primarily by compromised hepatic immune tolerance, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Recent evidence positions macrophages as pivotal players in AILDs pathogenesis, attributable to their multifaceted roles in inflammation amplification, immune regulation, and fibrogenesis. In the context of AILDs, macrophages exhibit marked polarization imbalance, increased recruitment of monocytes, and impaired clearance of apoptotic cells. Through complex interactions with T lymphocytes and hepatic stellate cells, macrophages orchestrate a pathological milieu promoting inflammation and fibrosis. Notably, diverse programmed cell death (PCD) modalities—autophagy, necroptosis, pyroptosis, and ferroptosis—not only determine macrophage survival and functional phenotype but also significantly impact cytokine release, phenotypic plasticity, and the trajectory of immunopathological progression. This review synthesizes current understandings of macrophage-driven immunoregulatory mechanisms in AILDs, characterizes the regulatory attributes of various macrophage-related PCD processes, and evaluates their relevance in experimental disease models. Furthermore, we highlight recent advancements in biomarker identification and targeted therapeutic strategies. Comprehensive elucidation of the interplay between macrophage immunological activity and programmed cell death pathways promises to inform novel, personalized therapeutic approaches for patients with AILDs.